SIA FUNDS, EL FONDO QUE CONFÍA EN GRÍFOLS SE POSICIONA EN CONTRA DE LA OPA .
15 mayo 2008
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer .
Verified by National Cancer Institute (NCI), May 2008
‹
›
Inicio
Ver versión web